Atossa Therapeutics (ATOS) Buy, Sell or Hold

Atossa Therapeutics (ATOS)

2.01

-0.00 (0.00%)

as of Jun 18, 2026, 11:18:07 pm Market Open.

2 watching

BUY

Allan Tong’s Discover Picks Two analysts rate ATOS stock a buy with a price target of $7.50 or 41% upside. Again, this is purely a speculative play and a volatile one with a 2.21 beta though it is a recovery stock. Fundamentals are spotty with insufficient data on Atossa’s margins and price earnings, so you’re betting on AT-H201, much like the market was wagering on who would win the vaccine sweepstakes 16 months ago. Read 3 Post-Covid Recovery Stocks to Buy for our full analysis.

Showing 1 to 1 of 1 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Atossa Therapeutics (ATOS) Frequently Asked Questions

What is Atossa Therapeutics stock symbol?

Atossa Therapeutics is a American stock, trading under the symbol ATOS (previously ATOS-Q on Stockchase) on the NASDAQ (ATOS). It is usually referred to as NASDAQ:ATOS or ATOS

Is Atossa Therapeutics a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on ATOS (previously ATOS-Q on Stockchase) on Stockchase. Read the latest expert commentary for Atossa Therapeutics.

Is Atossa Therapeutics a good investment or a top pick?

Atossa Therapeutics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Atossa Therapeutics.

Why is Atossa Therapeutics stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Atossa Therapeutics.

Is Atossa Therapeutics worth watching?

Atossa Therapeutics is covered by Stockchase experts and is worth watching.

What is Atossa Therapeutics stock price?

On 2026-06-18, Atossa Therapeutics (ATOS) stock closed at a price of $2.01.

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Atossa Therapeutics (ATOS)

Atossa Therapeutics(ATOS)

Atossa Therapeutics (ATOS) Frequently Asked Questions